PHASE I STUDY OF A NEW CANCER VACCINE OF TEN MIXED PEPTIDES FOR ADVANCED CANCER PATIENTS
Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.
TUMOR VACCINES AND CELLULAR IMMUNOTHERAPIES
Tumor Vaccines and Cellular Immunotherapies.
PANCREATIC CANCER ACTIONABLE GENES IN PRECISION MEDICINE AND PERSONALIZED SURGERY
Pancreatic cancer actionable genes in precision medicine and personalized surgery. Surgeon. 2016 Jun 28. pii: S1479-666X(16)30021-X.
INNOVATIVE EXPLORATORY CLINICAL APPROACHES FOR RELAPSED AND/OR REFRACTORY METASTATIC EWING’S SARCOMA
Review: Innovative Exploratory Clinical Approaches for Relapsed and/or Refractory Metastatic Ewing’s Sarcoma. Pediatric Cancers – Clinics in Oncology. 2016 Sept 08;1:1079.
PHASE II STUDY OF VIGIL® DNA ENGINEERED IMMUNOTHERAPY AS MAINTENANCE IN ADVANCED STAGE OVARIAN CANCER
Phase II Study of Vigil™ DNA Engineered Immunotherapy as Maintenance in Advanced Stage Ovarian Cancer. Gynecologic Oncology.
FOLLOW-UP OF BI-SHRNA FURIN /GM-CSF ENGINEERED AUTOLOGOUS TUMOR CELL (EATC) IMMUNOTHERAPY VIGIL® IN PATIENTS WITH ADVANCED MELANOMA
Follow-up of bi-shRNAfurin /GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma.
SAFETY AND EFFICACY IN ADVANCED SOLID TUMORS OF A TARGETED NANOPLEX CARRYING THE P53 GENE USED IN COMBINATION WITH DOCETAXEL: A PHASE IB STUDY
Safety and Efficacy in Advanced Solid Tumors of Docetaxel in Combination with a Targeted Nanocomplex Carrying the p53 Gene: A Phase Ib Study.
PRECLINICAL BIODISTRIBUTION AND SAFETY EVALUATION OF A PBI-SHRNA STMN1 LIPOPLEX AFTER SUBCUTANEOUS DELIVERY
Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery. Toxilogical Sciences.
METFORMIN RESTRAINS PANCREATIC DUODENAL HOMEOBOX-1 (PDX-1) FUNCTION BY INHIBITING ERK SIGNALING IN PANCREATIC DUCTAL ADENOCARCINOMA
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma. Curr Mol Med.
THE EFFECT OF A HIGH-FAT MEAL ON THE PHARMACOKINETICS OF IXAZOMIB, AN ORAL PROTEASOME INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. J Clin Pharmacol.